Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP)

被引：0
|
作者：
Van Wart, SA [1 ]
Cirincione, BB [1 ]
Ludwig, EA [1 ]
Chen, X [1 ]
Shoaf, S [1 ]
Grasela, TH [1 ]
Mallikaarjun, S [1 ]
机构：
[1] Cognigen Corp, Otsuka Maryland Res Inst, Buffalo, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P1 / P1
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients
    Bellissant, E
    Giudicelli, JF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (01) : 25 - 33
  • [22] Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
    Nodari, Savina
    Jao, Geoffrey T.
    Chiong, Jun R.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2010, 3 : 51 - 60
  • [23] Tolvaptan in patients with heart failure and hyponatremia: a single center experience
    Melero-Ferrer, J.
    Sanchez Lazaro, I. J.
    Ruiz-Ramos, J.
    Marques-Sule, E.
    Montero-Hernandez, M.
    Martinez-Dolz, L.
    Rodriguez, Y.
    Poveda-Andres, J. L.
    Almenar-Bonet, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 340 - 340
  • [24] Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study
    Kida, Keisuke
    Shibagaki, Yugo
    Tominaga, Naoto
    Matsumoto, Naoki
    Akashi, Yoshihiro J.
    Miyake, Fumihiko
    Kimura, Kenjiro
    CLINICAL PHARMACOKINETICS, 2015, 54 (03) : 273 - 284
  • [25] Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study
    Keisuke Kida
    Yugo Shibagaki
    Naoto Tominaga
    Naoki Matsumoto
    Yoshihiro J. Akashi
    Fumihiko Miyake
    Kenjiro Kimura
    Clinical Pharmacokinetics, 2015, 54 : 273 - 284
  • [26] CONGESTIVE-HEART-FAILURE (CHF) IN DIALYSIS PATIENTS
    PARFREY, PS
    HARNETT, JD
    GRIFFITHS, SM
    GAULT, MH
    BARRE, PE
    CLINICAL RESEARCH, 1986, 34 (03): : A862 - A862
  • [27] CONGESTIVE-HEART-FAILURE (CHF) IN DIALYSIS PATIENTS
    PARFREY, PS
    HARNETT, JD
    GRIFFITHS, SM
    GAULT, MH
    BARRE, PE
    KIDNEY INTERNATIONAL, 1987, 31 (01) : 240 - 240
  • [28] ANEMIA IN HOSPITALIZED CONGESTIVE HEART FAILURE (CHF) PATIENTS
    Puente, D.
    Descalzo, M.
    Forastiero, R.
    Perea, E.
    Ratto, R.
    Colorio, C.
    Rossi, A.
    Tabares, M.
    Favaloro, L.
    Pombo, G.
    Diez, M.
    Feldman, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 485 - 485
  • [29] Pharmacokinetic/pharmacodynamic/(PK/PD) model for abciximab in healthy subjects.
    Abernethy, DR
    Pezzullo, J
    Freedman, J
    Mascelli, MA
    Frederick, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 141 - 141
  • [30] The Efficacy and Safety of Tolvaptan Treatment in Patients with Congestive Heart Failure
    Seo, Yoshihiro
    Ishizu, Tomoko
    Sakai, Satoshi
    Kawano, Satoru
    Aonuma, Kazutaka
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S155 - S155
12345